Which has better earnings and valuation, GNLX or STRO?

Genelux has higher earnings, but lower revenue than Sutro Biopharma. Genelux is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genelux $10K 13,272.64 -$32.15M -$0.85 N/A Sutro Biopharma $102.48M 4.50 -$191.09M -$11.04 N/A

Is GNLX or STRO more profitable?

Genelux has a net margin of 0.00% compared to Sutro Biopharma's net margin of -154.21%. Sutro Biopharma's return on equity of 0.00% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -174.55% -123.65% Sutro Biopharma -154.21% N/A -69.20%

Does the media prefer GNLX or STRO?

In the previous week, Genelux and Genelux both had 2 articles in the media. Genelux's average media sentiment score of 0.93 equaled Sutro Biopharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genelux 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sutro Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, OVID or GNLX?

Ovid Therapeutics has higher revenue and earnings than Genelux. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ovid Therapeutics $7.25M 62.56 -$17.41M -$0.29 N/A Genelux $10K 13,272.64 -$32.15M -$0.85 N/A

Is OVID or GNLX more profitable?

Genelux has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Ovid Therapeutics' return on equity of -22.51% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Ovid Therapeutics -240.11% -22.51% -18.67% Genelux N/A -174.55% -123.65%

Does the media favor OVID or GNLX?

In the previous week, Ovid Therapeutics had 7 more articles in the media than Genelux. MarketBeat recorded 9 mentions for Ovid Therapeutics and 2 mentions for Genelux. Genelux's average media sentiment score of 0.93 beat Ovid Therapeutics' score of 0.26 indicating that Genelux is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ovid Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Genelux 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GNLX or NVCT more profitable?

Nuvectis Pharma's return on equity of -161.00% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -174.55% -123.65% Nuvectis Pharma N/A -161.00% -98.88%

Does the media refer more to GNLX or NVCT?

In the previous week, Nuvectis Pharma had 1 more articles in the media than Genelux. MarketBeat recorded 3 mentions for Nuvectis Pharma and 2 mentions for Genelux. Genelux's average media sentiment score of 0.93 beat Nuvectis Pharma's score of 0.90 indicating that Genelux is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genelux 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvectis Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, OCGN or GNLX?

Genelux has lower revenue, but higher earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ocugen $4.41M 108.23 -$67.85M -$0.24 N/A Genelux $10K 13,272.64 -$32.15M -$0.85 N/A

Is OCGN or GNLX more profitable?

Genelux's return on equity of -174.55% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen N/A -127,987.80% -135.48% Genelux N/A -174.55% -123.65%

Does the media refer more to OCGN or GNLX?

In the previous week, Ocugen had 2 more articles in the media than Genelux. MarketBeat recorded 4 mentions for Ocugen and 2 mentions for Genelux. Genelux's average media sentiment score of 0.93 beat Ocugen's score of 0.47 indicating that Genelux is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genelux 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, PRTA or GNLX?

Genelux has lower revenue, but higher earnings than Prothena. Genelux is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prothena $9.68M 47.75 -$244.09M -$2.82 N/A Genelux $10K 13,272.64 -$32.15M -$0.85 N/A

Is PRTA or GNLX more profitable?

Genelux has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Prothena -260.92% -43.44% -36.87% Genelux N/A -174.55% -123.65%

Does the media favor PRTA or GNLX?

In the previous week, Prothena had 2 more articles in the media than Genelux. MarketBeat recorded 4 mentions for Prothena and 2 mentions for Genelux. Prothena's average media sentiment score of 0.96 beat Genelux's score of 0.93 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genelux 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Genelux (GNLX) Competitors

$2.96 -0.07 (-2.31%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$2.96 0.00 (-0.03%)

As of 04:55 AM Eastern

Compare

GNLX vs. STRO, OVID, NVCT, OCGN, and PRTA

Should you buy Genelux stock or one of its competitors? MarketBeat compares Genelux with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genelux include Sutro Biopharma (STRO), Ovid Therapeutics (OVID), Nuvectis Pharma (NVCT), Ocugen (OCGN), and Prothena (PRTA). These companies are all part of the "pharmaceutical products" industry.

How does Genelux compare to Sutro Biopharma?

Genelux (NASDAQ:GNLX) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

Genelux has higher earnings, but lower revenue than Sutro Biopharma. Genelux is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	13,272.64	-$32.15M	-$0.85	N/A
Sutro Biopharma	$102.48M	4.50	-$191.09M	-$11.04	N/A

Genelux presently has a consensus price target of $18.00, indicating a potential upside of 508.11%. Sutro Biopharma has a consensus price target of $52.44, indicating a potential upside of 88.38%. Given Genelux's higher probable upside, research analysts plainly believe Genelux is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92

Genelux has a net margin of 0.00% compared to Sutro Biopharma's net margin of -154.21%. Sutro Biopharma's return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
Sutro Biopharma	-154.21%	N/A	-69.20%

37.3% of Genelux shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 7.5% of Genelux shares are held by insiders. Comparatively, 1.8% of Sutro Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Genelux has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market.

In the previous week, Genelux and Genelux both had 2 articles in the media. Genelux's average media sentiment score of 0.93 equaled Sutro Biopharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genelux	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sutro Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sutro Biopharma beats Genelux on 9 of the 15 factors compared between the two stocks.

How does Genelux compare to Ovid Therapeutics?

Ovid Therapeutics (NASDAQ:OVID) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

Ovid Therapeutics has higher revenue and earnings than Genelux. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	62.56	-$17.41M	-$0.29	N/A
Genelux	$10K	13,272.64	-$32.15M	-$0.85	N/A

Ovid Therapeutics has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market. Comparatively, Genelux has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

In the previous week, Ovid Therapeutics had 7 more articles in the media than Genelux. MarketBeat recorded 9 mentions for Ovid Therapeutics and 2 mentions for Genelux. Genelux's average media sentiment score of 0.93 beat Ovid Therapeutics' score of 0.26 indicating that Genelux is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genelux	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ovid Therapeutics presently has a consensus target price of $5.13, indicating a potential upside of 110.91%. Genelux has a consensus target price of $18.00, indicating a potential upside of 508.11%. Given Genelux's higher possible upside, analysts clearly believe Genelux is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 7.0% of Ovid Therapeutics shares are owned by insiders. Comparatively, 7.5% of Genelux shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Genelux has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Ovid Therapeutics' return on equity of -22.51% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-22.51%	-18.67%
Genelux	N/A	-174.55%	-123.65%

Summary

Ovid Therapeutics beats Genelux on 10 of the 17 factors compared between the two stocks.

How does Genelux compare to Nuvectis Pharma?

Genelux (NASDAQ:GNLX) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

Nuvectis Pharma's return on equity of -161.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
Nuvectis Pharma	N/A	-161.00%	-98.88%

Nuvectis Pharma has lower revenue, but higher earnings than Genelux. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	13,272.64	-$32.15M	-$0.85	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

Genelux has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.24, indicating that its share price is 124% less volatile than the broader market.

In the previous week, Nuvectis Pharma had 1 more articles in the media than Genelux. MarketBeat recorded 3 mentions for Nuvectis Pharma and 2 mentions for Genelux. Genelux's average media sentiment score of 0.93 beat Nuvectis Pharma's score of 0.90 indicating that Genelux is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genelux	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvectis Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genelux presently has a consensus price target of $18.00, suggesting a potential upside of 508.11%. Nuvectis Pharma has a consensus price target of $35.00, suggesting a potential upside of 89.80%. Given Genelux's stronger consensus rating and higher possible upside, analysts plainly believe Genelux is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

37.3% of Genelux shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 7.5% of Genelux shares are held by company insiders. Comparatively, 28.6% of Nuvectis Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Genelux beats Nuvectis Pharma on 8 of the 14 factors compared between the two stocks.

How does Genelux compare to Ocugen?

Ocugen (NASDAQ:OCGN) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Genelux's return on equity of -174.55% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-135.48%
Genelux	N/A	-174.55%	-123.65%

Genelux has lower revenue, but higher earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	108.23	-$67.85M	-$0.24	N/A
Genelux	$10K	13,272.64	-$32.15M	-$0.85	N/A

10.3% of Ocugen shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 4.0% of Ocugen shares are owned by company insiders. Comparatively, 7.5% of Genelux shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Ocugen currently has a consensus target price of $9.50, indicating a potential upside of 573.76%. Genelux has a consensus target price of $18.00, indicating a potential upside of 508.11%. Given Ocugen's stronger consensus rating and higher probable upside, equities analysts clearly believe Ocugen is more favorable than Genelux.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Ocugen had 2 more articles in the media than Genelux. MarketBeat recorded 4 mentions for Ocugen and 2 mentions for Genelux. Genelux's average media sentiment score of 0.93 beat Ocugen's score of 0.47 indicating that Genelux is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genelux	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ocugen has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market. Comparatively, Genelux has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

Summary

Genelux beats Ocugen on 8 of the 15 factors compared between the two stocks.

How does Genelux compare to Prothena?

Prothena (NASDAQ:PRTA) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

Prothena presently has a consensus price target of $23.75, suggesting a potential upside of 168.97%. Genelux has a consensus price target of $18.00, suggesting a potential upside of 508.11%. Given Genelux's higher probable upside, analysts plainly believe Genelux is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Prothena had 2 more articles in the media than Genelux. MarketBeat recorded 4 mentions for Prothena and 2 mentions for Genelux. Prothena's average media sentiment score of 0.96 beat Genelux's score of 0.93 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genelux	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genelux has lower revenue, but higher earnings than Prothena. Genelux is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	47.75	-$244.09M	-$2.82	N/A
Genelux	$10K	13,272.64	-$32.15M	-$0.85	N/A

Prothena has a beta of -0.31, suggesting that its stock price is 131% less volatile than the broader market. Comparatively, Genelux has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

Genelux has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-260.92%	-43.44%	-36.87%
Genelux	N/A	-174.55%	-123.65%

97.1% of Prothena shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 10.4% of Prothena shares are owned by insiders. Comparatively, 7.5% of Genelux shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Prothena beats Genelux on 11 of the 17 factors compared between the two stocks.

Get Genelux News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNLX vs. The Competition

Export

Metric	Genelux	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$135.87M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-3.48	20.85	27.11	24.26
Price / Sales	13,272.64	314.01	589.18	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	9.87	8.49	10.73	6.29
Net Income	-$32.15M	$23.83M	$3.58B	$330.66M
7 Day Performance	-0.34%	-3.56%	-2.11%	-1.35%
1 Month Performance	N/A	6.31%	3.27%	-0.64%
1 Year Performance	-12.43%	48.30%	26.32%	19.08%

Genelux Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNLX Genelux	2.245 of 5 stars	$2.96 -2.3%	$18.00 +508.1%	-13.7%	$135.87M	$10K	N/A	10	Positive News
STRO Sutro Biopharma	2.9665 of 5 stars	$32.13 +4.9%	$52.44 +63.2%	+265.6%	$532.39M	$102.48M	N/A	240	High Trading Volume
OVID Ovid Therapeutics	2.691 of 5 stars	$2.76 +5.7%	$5.13 +85.7%	+500.0%	$515.13M	$7.25M	N/A	60	Short Interest Increase
NVCT Nuvectis Pharma	4.1112 of 5 stars	$19.20 -2.2%	$35.00 +82.3%	+134.0%	$509.38M	N/A	N/A	8	High Trading Volume
OCGN Ocugen	2.3773 of 5 stars	$1.50 +0.7%	$9.50 +533.3%	+23.7%	$507.78M	$4.41M	N/A	80	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNLX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genelux (GNLX) Competitors

GNLX vs. STRO, OVID, NVCT, OCGN, and PRTA

How does Genelux compare to Sutro Biopharma?

Summary

How does Genelux compare to Ovid Therapeutics?

Summary

How does Genelux compare to Nuvectis Pharma?

Summary

How does Genelux compare to Ocugen?

Summary

How does Genelux compare to Prothena?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNLX vs. The Competition

Genelux Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genelux (GNLX) Competitors

GNLX vs. STRO, OVID, NVCT, OCGN, and PRTA

How does Genelux compare to Sutro Biopharma?

Which has better earnings and valuation, GNLX or STRO?

Do analysts rate GNLX or STRO?

Is GNLX or STRO more profitable?

Do insiders and institutionals believe in GNLX or STRO?

Which has more risk and volatility, GNLX or STRO?

Does the media prefer GNLX or STRO?

Summary

How does Genelux compare to Ovid Therapeutics?

Which has better earnings & valuation, OVID or GNLX?

Which has more risk & volatility, OVID or GNLX?

Does the media favor OVID or GNLX?

Do analysts prefer OVID or GNLX?

Do institutionals & insiders have more ownership in OVID or GNLX?

Is OVID or GNLX more profitable?

Summary

How does Genelux compare to Nuvectis Pharma?

Is GNLX or NVCT more profitable?

Which has preferable earnings & valuation, GNLX or NVCT?

Which has more volatility and risk, GNLX or NVCT?

Does the media refer more to GNLX or NVCT?

Do analysts recommend GNLX or NVCT?

Do insiders & institutionals have more ownership in GNLX or NVCT?

Summary

How does Genelux compare to Ocugen?

Is OCGN or GNLX more profitable?

Which has better earnings & valuation, OCGN or GNLX?

Do institutionals & insiders have more ownership in OCGN or GNLX?

Do analysts rate OCGN or GNLX?

Does the media refer more to OCGN or GNLX?

Which has more risk & volatility, OCGN or GNLX?

Summary

How does Genelux compare to Prothena?

Do analysts recommend PRTA or GNLX?

Does the media favor PRTA or GNLX?

Which has stronger earnings and valuation, PRTA or GNLX?

Which has more volatility and risk, PRTA or GNLX?

Is PRTA or GNLX more profitable?

Do institutionals & insiders hold more shares of PRTA or GNLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNLX vs. The Competition

Genelux Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools